Chicago, IL, November 3, 2022 (PRNewswire) -- Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial and potential commercialization of a new class of drug for patients with Tourette Syndrome.
Read full article here.
San Diego, CA, April 3, 2024 (Reuters) -- Alterome Therapeutics announced that it has successfully secured $132 million. Spearheaded by Goldman Sachs Alternatives, this a series B financing brings f
Henderson, NV, April 8, 2024 (Zura Bio) -- Zura Bio, a company focused on advancing treatments for autoimmune and inflammatory conditions, has named Robert Lisicki as its new Chief Executive Officer
Cambridge, MA, April 3, 2024 (Business Wire) -- Obsidian Therapeutics, Inc., a cutting-edge clinical-stage biotechnology company specializing in engineered cell and gene therapies, recently conclude
